ATNM
Actinium Pharmaceuticals, Inc.
Key Financials
Operating Income
$-36247000
↑ 13.9%
Revenue
$90000
↑ 11.1%
Gross Profit
$0
NaN%
Total Assets
$51.8M
↓ 32.7%
Net Income
$-33887000
↑ 11.4%
Shareholders' Equity
$7.8M
↓ 76.1%
Total Liabilities
$43.9M
↓ 0.5%
EPS (Diluted)
$-1.09
↑ 14.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 3 | 9/10/2026 | View on SEC |
| 3 | 9/10/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ATNM |
| Company Name | Actinium Pharmaceuticals, Inc. |
| CIK | 1388320 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (646) 677-3870 |